OncoMatch/Clinical Trials/NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Is NCT06121843 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for multiple myeloma.
Treatment: BMS-986393 · Alnuctamab · Mezigdomide · Iberdomide · Elranatamab · Dexamethasone — The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-myeloma therapy
treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E)
Cannot have received: alnuctamab (alnuctamab)
Prior treatment with alnuctamab (Arm A)
Cannot have received: mezigdomide (mezigdomide)
Prior treatment with mezigdomide (Arms B and E)
Cannot have received: iberdomide (iberdomide)
Prior treatment with iberdomide (Arm C)
Cannot have received: elranatamab (elranatamab)
Prior treatment with elranatamab (Arm D)
Cannot have received: BCMA-targeting therapy
Prior treatment with BCMA-targeting therapy (Part 2 Arms A and D)
Cannot have received: GPRC5D-targeting therapy
Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Mayo Clinic in Arizona - Phoenix · Phoenix, Arizona
- City of Hope Comprehensive Cancer Center · Duarte, California
- Mayo Clinic in Florida · Jacksonville, Florida
- Northside Hospital · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06121843 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior alnuctamab, mezigdomide, iberdomide disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages